Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kronos Bio Inc (KRON)

Kronos Bio Inc (KRON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 53,725
  • Shares Outstanding, K 61,051
  • Annual Sales, $ 9,850 K
  • Annual Income, $ -86,080 K
  • EBIT $ -70 M
  • EBITDA $ -71 M
  • 60-Month Beta 1.63
  • Price/Sales 5.46
  • Price/Cash Flow N/A
  • Price/Book 0.67
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.07
  • Most Recent Earnings $-0.14 on 05/08/25
  • Next Earnings Date 08/14/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.31
  • Number of Estimates 1
  • High Estimate -0.31
  • Low Estimate -0.31
  • Prior Year -0.27
  • Growth Rate Est. (year over year) -14.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6565 +34.04%
on 06/02/25
0.8997 -2.19%
on 06/10/25
+0.2049 (+30.35%)
since 05/20/25
3-Month
0.6500 +35.38%
on 05/15/25
0.9490 -7.27%
on 03/24/25
unch (unch)
since 03/20/25
52-Week
0.6500 +35.38%
on 05/15/25
1.6000 -45.00%
on 07/16/24
-0.1600 (-15.38%)
since 06/20/24

Most Recent Stories

More News
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

KRON : 0.8800 (+1.49%)
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

KRON : 0.8800 (+1.49%)
Kronos Bio Announces Leadership Change with Deborah Knobelman Appointed as President and Interim CEO

Kronos Bio appoints Deborah Knobelman as President and Interim CEO, succeeding Norbert Bischofberger amidst significant workforce reduction.Quiver AI SummaryKronos Bio, Inc. announced that Dr. Deborah...

KRON : 0.8800 (+1.49%)
Kronos Bio Stock Jumps After Deep Workforce Cuts And CEO Shuffle: Retail Aligns With Shake-Up

The company said this move is part of a broader strategy to implement cost-cutting measures.

IWC : 162.64 (+0.19%)
KRON : 0.8800 (+1.49%)
VXF : 212.66 (-0.02%)
VTI : 336.23 (-0.10%)
Kronos Bio Announces CEO Transition and Reduction in Force

KRON : 0.8800 (+1.49%)
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

KRON : 0.8800 (+1.49%)
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

KRON : 0.8800 (+1.49%)
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

KRON : 0.8800 (+1.49%)
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

KRON : 0.8800 (+1.49%)
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

KRON : 0.8800 (+1.49%)

Business Summary

Kronos Bio Inc. is a clinical-stage biopharmaceutical company. It engages in discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Kronos Bio Inc. is headquartered in San Mateo, Calif.

See More

Key Turning Points

3rd Resistance Point 0.8950
2nd Resistance Point 0.8880
1st Resistance Point 0.8840
Last Price 0.8800
1st Support Level 0.8730
2nd Support Level 0.8660
3rd Support Level 0.8620

See More

52-Week High 1.6000
Fibonacci 61.8% 1.2371
Fibonacci 50% 1.1250
Fibonacci 38.2% 1.0129
Last Price 0.8800
52-Week Low 0.6500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar